MANNKIND CORP (MNKD) — SEC Financial Statements & Analysis

MANNKIND CORP (MNKD) is a pharmaceutical preparations company, incorporated in DE. MANNKIND CORP trades on Nasdaq as: MNKD. MANNKIND CORP (MNKD)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, MANNKIND CORP carries a market cap of $1.32B, a P/E ratio of -30.20x, a P/B ratio of -19.60x, a P/S ratio of 3.35x, an enterprise value of $1.26B, and an EV/EBITDA multiple of 42.05x. On profitability, it posts a gross margin of 85.82%, an operating margin of 2.34%, a net margin of -11.08%, a Return on Equity (ROE) of 71.36%, and a Return on Assets (ROA) of -7.62%. Per share, it reports EPS of $-0.14, diluted EPS of $-0.14, free cash flow per share of $-0.06, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 30.46% year-over-year, net income growth of -232.98% year-over-year, and EPS growth of -231.16% year-over-year. On the balance sheet, it maintains a current ratio of 1.72x, a quick ratio of 1.08x, working capital of $102.81M, a debt-to-equity ratio of -11.90x, a debt ratio of 1.09, an interest coverage ratio of 0.33x, free cash flow of $-18.14M (TTM), and net debt of $-52.93M. Figures sourced from SEC EDGAR.

Market Cap

$1.32B

P/E TTM

-30.20x

EPS TTM

$-0.14

P/B TTM

-19.60x

ROE TTM

71.36%

ROA TTM

-7.62%

Debt To Equity

-11.90x

Free Cash Flow TTM

$-18.14M

Net Revenue TTM Growth 1Y

30.46%

Data as of 2026-06-30 · Source: SEC EDGAR